Joyner’s comments were his first made publicly since he was promoted less than a month ago to replace Karen S. Lynch, who stepped down. CVS Health has struggled to control costs in its Aetna health ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Longtime CVS Health executive David Joyner has replaced Karen Lynch as CEO, as the company struggles to drive higher profits and stock performance, CVS announced Friday. The move, effective ...

J.P. Morgan analyst Lisa Gill maintained a Buy rating on CVS Health (CVS – Research Report) yesterday and set a price target of $80.00. The company’s shares closed yesterday at $54.03. Gill covers the ...

For CVS, this year has been defined by an unsuccessful fight against elevated medical costs. The third quarter was no different. “We have been more acutely impacted than others in the industry ...

The executive shakeup comes as CVS has faced a declining stock price since 2021 and recent high medical costs, especially in Medicare Advantage. The pharmacy giant slashed its earnings outlook ...

Charles Rhyee, an analyst from TD Cowen, maintained the Buy rating on CVS Health (CVS – Research Report). The associated price target was ...

America’s largest drug store chain named a new chief executive officer on Friday, with longtime CVS Health executive David Joyner replacing Karen Lynch. CVS also withdrew its 2024 profit ...

By Danielle Kaye CVS Health abruptly ousted its chief executive, Karen S. Lynch, on Friday as the pharmacy and health care conglomerate struggled with sluggish growth and faced pressure from ...